IDEAYA Biosciences, Inc. (IDYA) Citi Annual World Healthcare Convention 2025 December 2, 2025 9:00 AM EST
Firm Members
Yujiro Hata – Founder, President, CEO & Director
Joshua Bleharski – Chief Monetary Officer
Convention Name Members
Yigal Nochomovitz – Citigroup Inc., Analysis Division
Presentation
Yigal Nochomovitz
Citigroup Inc., Analysis Division
Welcome, everybody, to day 1 of Citi’s World Healthcare Convention right here in sunny and hopefully very heat Miami. I am Dov Nochomovitz, one of many biotech analysts at Citi. So the primary session, it is my pleasure to have with me the administration of IDEAYA Biosciences. We have been masking them for fairly a very long time. I feel because the first day they have been public, if I am not mistaken. And I’ve Yujiro Hata, the CEO; and Joshua Bleharski, who’s the CFO. So welcome. Thanks each very, very a lot. And I used to be simply saying to Yujiro, that point is flying. They only had their massive R&D Day in New York only a few months in the past.
Query-and-Reply Session
Yigal Nochomovitz
Citigroup Inc., Analysis Division
So Yujiro, rather a lot’s occurred. You’ve gotten loads of updates during the last a number of months. You’ve gotten an enormous catalyst coming as we all know. However perhaps simply to start out out, should you might present only a fast overview of IDEAYA, what the producing thesis was for the corporate? What are the large applications, and we will transfer into a number of the massive updates coming.
Yujiro Hata
Founder, President, CEO & Director
Sure, for positive. So thanks a lot, Yigal, for inviting us once more this yr to your annual Healthcare Convention at Citi. So IDEAYA Biosciences, we’re a number one precision drugs oncology firm. We’ve now 8 applications in scientific growth. Yigal, as you understand, our lead program, darovasertib, is in our first-line registrational trial in metastatic uveal melanoma. We’re shifting nearer in direction of our prime line outcomes to hopefully allow
